Chidamide (CS055/HBI-8000): A new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 901-909

  Ning, Zhi Qiang ^a   Li, Zhi Bin ^a   Newman, Michael J ^b,e   Shan, Song ^a   Wang, Xin Hao ^a   Pan, De Si ^a   Zhang, Jin ^c   Dong, Mei ^c   Du, Xin ^d   Lu, Xian Ping ^a  

^a Chipscreen Biosciences Ltd   (China)

^b HUYA Bioscience International   (United States)

^c CANCER HOSPITAL   (China)

^d Hematology Department   (China)

^e Aaxiion Therapeutics Inc   (United States)

Author keywords

Antitumor activity; Chidamide; HDAC inhibitor; Immune cell mediated cytotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CHIDAMIDE; CS 055; HBI 8000; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL FUNCTION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; TUMOR CELL CULTURE; TUMOR CELL LINE; UPREGULATION;

ACETYLATION; AMINOPYRIDINES; ANIMALS; BENZAMIDES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; IMMUNITY, CELLULAR; ISOENZYMES; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859787650     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1766-x     Document Type: Article

References (25)

1. Khan AU, Krishnamurthy S (2005) Histone modifications as key regulators of transcription. Front Biosci 10:866-872
2. Graham JS, Kaye SB, Brown R (2009) The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 45:1129-1136
3. Inoue S, Mai A, Dyer MJ, Cohen GM (2006) Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 66:6785-6792 (Pubitemid 44085638)
4. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, Tsuneyoshi M (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18:769-774
5. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98:604-610 (Pubitemid 351214528)
6. Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA, Bang YJ, Kim TY (2008) Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 368:318-322
7. Paris M, Porcelloni M, Binaschi M, Fattori D (2008) Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51:1505-1529 (Pubitemid 351438836)
8. Noureen N, Rashid H, Kalsoom S (2010) Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol 66(4):625-633
9. FDA (2006) US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products (OODP). Approval letter for ZOLINZA™, NDA 21-991, Merck and Co. Inc. 6 Oct 2006
10. FDA (2009) US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products (OODP). Approval letter for ISTODAX, NDA 022393, Gloucester Pharmaceuticals. 5 Nov 2009
11. FDA (2011) US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products (OODP). Approval letter for ISTODAX, NDA 022393/S-004, Celgene Corporation. 16 Jun 2011
12. Xie AH, Li BY, Liao CZ, Li ZB, Lu XP, Shi LM, Zhou JJ (2004) Docking study of HDAC: implication for benzamide inhibitors binding mode. Acta Phys-Chim Sin 20:569-572
13. Xie AH, Liao CZ, Li ZB, Ning ZQ, Hu W, Lu XP, Shi LM, Zhou J (2004) Quantitative structure-activity relationship study of histone deacetylase inhibitors. Curr Med Chem Anticancer Agents 4:273-299 (Pubitemid 38647587)
14. Yin ZH, Wu ZW, Lan YK, Liao CZ, Shan S, Li ZL, Ning ZQ, Lu XP, Li ZB (2004) Synthesis of chidamide, a new histone deacetylase (HDAC) inhibitor. Chin J New Drugs 13:536-538
15. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. PNAS 96:4592-4597 (Pubitemid 29190381)
16. Hess-Stumpp H, Bracker TU, Henderson D, Politz O (2007) MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol 39:1388-1405 (Pubitemid 47031032)
17. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumour activity in vitro and in vivo. Mol Cancer Ther 7:759-768 (Pubitemid 351551029)
18. Park BL, Kim YJ, Cheong HS, Lee SO, Han CS, Yoon JH, Park JH, Chang HS, Park CS, Lee HS, Shin HD (2007) HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochem Biophys Res Commun 363:776-781 (Pubitemid 47520686)
19. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51 (Pubitemid 43054973)
20. Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11:4912-4922 (Pubitemid 41557212)
21. Qiang L, Xiao H, Campos EI, Ho VC, Li G (2005) Development of a PAN-specific, affinity-purified antiacetylated lysine antibody for detection, identification, isolation, and intracellular localization of acetylated protein. J Immunoass Immunochem 26:13-23 (Pubitemid 40250342)
22. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, Sanders K (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 121:1138-1148 (Pubitemid 47101654)
23. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589 (Pubitemid 351184977)
24. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N (2005) Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65:11136-11145 (Pubitemid 41713385)
25. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65:6321-6329 (Pubitemid 40994418)